Immunotherapy before surgery shows promise against lung cancer

NCT ID NCT02259621

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Dec 18, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) before surgery to people with early-stage non-small cell lung cancer. The goal was to see if it is safe and can shrink tumors before removal. 39 participants received treatment, and researchers looked at how well the tumors responded and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Johnathan Spicer

Montreal, Quebec, H4 3J1, Canada
Johns Hopkins at Bayview Medical Center

Baltimore, Maryland, 21224, United States
Memorial Sloan Kettering

New York, New York, 10065, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
Swedish Cancer Insitute

Edmonds, Washington, 98026, United States

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER